Abraxane Induced Life-threatening Toxicities with Metastatic Breast Cancer and Hepatic Insufficiency

Overview

Journal Invest New Drugs

Publisher Springer

Specialty Oncology

Date 2006 Mar 1

PMID 16505953

Citations 9

Authors

J Lee Villano

Divyesh Mehta

Latha Radhakrishnan

Affiliations

Soon will be listed here.

Citing Articles

Three-dimensional (3D) liver cell models - a tool for bridging the gap between animal studies and clinical trials when screening liver accumulation and toxicity of nanobiomaterials.

Tutty M, Movia D, Prina-Mello A Drug Deliv Transl Res. 2022; 12(9):2048-2074.

PMID: 35507131 PMC: 9066991. DOI: 10.1007/s13346-022-01147-0.

Iron oxide nanoparticle targeted chemo-immunotherapy for triple negative breast cancer.

Mu Q, Lin G, Jeon M, Wang H, Chang F, Revia R Mater Today (Kidlington). 2022; 50:149-169.

PMID: 34987308 PMC: 8722574. DOI: 10.1016/j.mattod.2021.08.002.

Toxicology of Nanoparticles in Drug Delivery.

Sharma S, Parveen R, Chatterji B Curr Pathobiol Rep. 2021; 9(4):133-144.

PMID: 34840918 PMC: 8611175. DOI: 10.1007/s40139-021-00227-z.

Synthetic low-density lipoprotein (sLDL) selectively delivers paclitaxel to tumor with low systemic toxicity.

Su H, Li X, Liang D, Qi X Oncotarget. 2016; 7(32):51535-51552.

PMID: 27409176 PMC: 5239495. DOI: 10.18632/oncotarget.10493.

Enhanced performance of macrophage-encapsulated nanoparticle albumin-bound-paclitaxel in hypo-perfused cancer lesions.

Leonard F, Curtis L, Yesantharao P, Tanei T, Alexander J, Wu M Nanoscale. 2016; 8(25):12544-52.

PMID: 26818212 PMC: 4919151. DOI: 10.1039/c5nr07796f.

References

Ibrahim N, Desai N, Legha S, Soon-Shiong P, Theriault R, Rivera E . Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res. 2002; 8(5):1038-44. View

van Schaik R . Implications of cytochrome P450 genetic polymorphisms on the toxicity of antitumor agents. Ther Drug Monit. 2004; 26(2):236-40. DOI: 10.1097/00007691-200404000-00027. View